|
Causative
Agent
Routes of Exposure
Infective Dose &
Infectivity
Incubation Period
Clinical Effects
Lethality
Transmissibility
Primary Contaminations & Methods of Dissemination
Secondary Contamination & Persistence of organism
Decontamination &
Isolation
Laboratory testing
Therapeutic Treatment
Prophylactic Treatment
Differential Diagnosis
References
Causative Agent:
Western Equine Encephalitis (WEE) is a
mosquito-borne illness caused by an alphavirus of the
Togaviridae family.
Routes of Exposure:
Humans are primarily exposed to WEE through the bite of an
infected mosquito.
Infective Dose &
Infectivity:
The
infective dose is unknown. All people are considered
susceptible though children are more likely to be severely
affected.
Incubation Period:
The incubation period is usually 5-10 days.
Clinical Effects:
Most infections are asymptomatic. Mild cases often
present with a nonspecific febrile illness or aseptic
meningitis. Severe infections are usually marked by
acute onset, headache, high fever, meningeal signs, stupor,
disorientation, coma, tremors, occasional convulsions
(especially infants) and spastic (but rarely flaccid)
paralysis. Physical examination typically reveals nuchal
rigidity, impaired sensorium, and upper motor neuron deficits
with pathologically abnormal reflexes.
Lethality:
The overall
mortality rate for WEE is less than 3-4%, but is closer to 10%
among children and older adults.
Transmissibility:
WEE infection occurs when a person is bitten by an infected
mosquito. The virus is not directly transmitted from
person-to-person.
Primary Contamination & Methods of Dissemination:
As a bioterrorism weapon, WEE would most likely be delivered
via aerosolization.
Secondary Contamination & Persistence of Organism:
Secondary transmission does not occur and WEE particles are
not considered to be stable in the environment.
Decontamination &
Isolation:
-
Patients
– Standard precautions should always be practiced.
Enteric precautions are appropriate for aseptic meningitis
of unknown etiology until enterovirus meningoencephalitis is
ruled out. When the diagnosis of WEE is known,
specific isolation procedures are not indicated.
-
Equipment,
clothing & other objects
– 0.5% hypochlorite solution (one part household bleach and
9 parts water = 0.5% solution) is effective for
environmental decontamination.
Laboratory testing:
By the end of the first week of illness IgM, hemagglutination
inhibition antibodies, and neutralizing antibodies can
generally be found. During the next week they increase
in titer. Complement fixation responses generally appear
in the second week and rise thereafter. Four-fold titer
rises are diagnostic, but because of serologic cross-reactions
with other alphaviruses, neutralization tests are preferred.
Examination of the CSF reveals a lymphocytic pleocytosis
ranging from 10 to 400 mononuclear cells per microliter.
WEE virus may occasionally be isolated from the CSF or throat
swabs taken within the first 2 days of illness and is
frequently recovered from brain tissue on postmortem
examination.
Therapeutic Treatment: There is no specific therapy. Patients
who develop severe illness may require anticonvulsant and
intensive supportive care to maintain fluid and electrolyte
balance, adequate ventilation, and to avoid complicating
secondary bacterial infections. The extremes of high
fever occasionally produced by WEE infection may require
aggressive antihyperthermia measures.
Prophylactic Treatment: An investigational formalin-inactivated vaccine
is available, but it is poorly immunogenic.
Differential Diagnosis: The differential diagnosis includes a number of
infections including cytomegalovirus, herpes simplex
encephalitis, St. Louis encephalitis, West Nile encephalitis,
eastern equine encephalitis, Venezuelan encephalitis,
leptospirosis, lyme disease, cat scratch disease, bacterial
meningitis, tuberculosis, fungal meningitis, malaria, and
Naegleria infection.
References:
-
Chin J.
Control of Communicable Diseases Manual, Seventeenth
Edition, American Public Health Association; 2000.
-
Smith JF,
Davis K, Hart MK, et al. Viral Encephalitides. In: Zajtchuk
R, Bellamy RF, eds. Medical Aspects of Chemical and
Biological Warfare. Washington, DC: Office of the Surgeon
General, U.S. Department of the Army; 1997:561-589.
For more
information call (602) 364-3289 |